NOVAVAX INC(NVAX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,815 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in NVAX
Events flagged as statistical outliers against NVAX's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-06
NVAX quality score dropped 47 points (66→19) on a new filing
View source filing →
NVAX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for NOVAVAX INC (NVAX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NVAX at 18.0/100 on a 32-signal composite quality model, placing it at rank #2,815 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.9) and profitability (9.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NOVAVAX INC reports quarterly revenue of $56.7M, net income of $-53.4M. Top institutional holders of NVAX by reported 13-F value include SHAH CAPITAL MANAGEMENT, BlackRock, STATE STREET, based on the most recent SEC filings. NVAX trades on the Nasdaq exchange and files with the SEC under CIK 1000694. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NOVAVAX INC directly from SEC EDGAR. NOVAVAX INC's 13F Pro composite quality score has ranged between 18 and 59 since 2021, currently 18.0 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$56.7M
Net Income
Q2 2026
$-53.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+64.7% YoYNet Income
+334.8% YoYOperating Income
+281.9% YoYEPS (Diluted)
+309.8% YoYTotal Assets
-24.6% YoYTotal Debt
Op. Cash Flow
-180.3% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.12B +64.7% | $682.2M -30.7% | $983.7M -50.4% | $1.98B +72.9% | $1.15B +141.0% | $475.6M |
| Net Income | $440.3M +334.8% | $-187.5M +65.6% | $-545.1M +17.2% | $-657.9M +62.3% | $-1.74B -316.9% | $-418.3M |
| Operating Income | $452.8M +281.9% | $-248.9M +56.1% | $-566.5M +12.1% | $-644.7M +61.8% | $-1.69B -304.7% | $-416.7M |
| EPS (Diluted) | $2.58 +309.8% | $-1.23 +77.3% | $-5.41 +35.7% | $-8.42 +64.1% | $-23.44 -222.4% | $-7.27 |
| Total Assets | $1.18B -24.6% | $1.56B -13.2% | $1.80B -20.4% | $2.26B -12.3% | $2.58B +62.8% | $1.58B |
| Total Debt | $244.2M | — | — | — | — | — |
| Operating Cash Flow | $-244.6M -180.3% | $-87.3M +87.8% | $-714.0M -71.7% | $-415.9M -228.8% | $322.9M +859.1% | $-42.5M |
| Free Cash Flow | — | — | — | — | $265.5M +373.2% | $-97.2M |
Get alerted when NVAX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NOVAVAX INC including:
Top Institutional Holders of NVAX
SHAH CAPITAL MANAGEMENT
$133.4M14,165,577 shBlackRock, Inc.
$131.4M13,946,881 shSTATE STREET CORP
$110.6M11,740,550 shVANGUARD PORTFOLIO MANAGEMENT LLC
$71.7M7,607,996 shVANGUARD CAPITAL MANAGEMENT LLC
$68.4M7,257,449 shSanofi
$64.8M6,880,481 shD. E. Shaw & Co., Inc.
$53.2M5,650,905 shGEODE CAPITAL MANAGEMENT, LLC
$39.6M4,207,370 shTWO SIGMA INVESTMENTS, LP
$38.5M4,091,043 shCOATUE MANAGEMENT LLC
$36.1M3,836,986 sh
| Fund | Value | Shares |
|---|---|---|
| SHAH CAPITAL MANAGEMENT | $133.4M | 14,165,577 |
| BlackRock, Inc. | $131.4M | 13,946,881 |
| STATE STREET CORP | $110.6M | 11,740,550 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $71.7M | 7,607,996 |
| VANGUARD CAPITAL MANAGEMENT LLC | $68.4M | 7,257,449 |
| Sanofi | $64.8M | 6,880,481 |
| D. E. Shaw & Co., Inc. | $53.2M | 5,650,905 |
| GEODE CAPITAL MANAGEMENT, LLC | $39.6M | 4,207,370 |
| TWO SIGMA INVESTMENTS, LP | $38.5M | 4,091,043 |
| COATUE MANAGEMENT LLC | $36.1M | 3,836,986 |
Companies Similar to NVAX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Sarepta Therapeutics, Inc.
Personalis, Inc.
QuidelOrtho Corp
SIGA TECHNOLOGIES INC
Teladoc Health, Inc.
Arcturus Therapeutics Holdings Inc.
Vanda Pharmaceuticals Inc.
Canopy Growth Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put NVAX on your watchlist
Track score changes the day NOVAVAX INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NVAX a good stock to buy?
13F Pro's AI-powered analysis of NOVAVAX INC (NVAX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NVAX are available on the NVAX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NVAX is classified as a small company.
Which hedge funds own NVAX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NVAX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NOVAVAX INC's investment landscape.